Cirrhosis

Incara IND for Liver Cell Transplantation Allowed by FDA

Published in Hepatitis Weekly, September 9th, 2002

Incara Pharmaceuticals Corporation (INCR) announced it has been notified by the U.S. Food and Drug Administration (FDA) of their allowance of Incara's investigational new drug application (IND) to begin phase I clinical trials of cryopreserved human liver cells for the treatment of patients with cirrhosis and end-stage liver disease.

Assuming adequate financial resources, the company intends to initiate clinical trials this fall.

"Allowance of our IND for liver cell therapy by the FDA is a tribute to the quality of the work performed by Incara's development team. Developing a pharmaceutical grade cell therapy product is a difficult task that applies...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-09-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry